CA2467717A1 - Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases - Google Patents
Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases Download PDFInfo
- Publication number
- CA2467717A1 CA2467717A1 CA002467717A CA2467717A CA2467717A1 CA 2467717 A1 CA2467717 A1 CA 2467717A1 CA 002467717 A CA002467717 A CA 002467717A CA 2467717 A CA2467717 A CA 2467717A CA 2467717 A1 CA2467717 A1 CA 2467717A1
- Authority
- CA
- Canada
- Prior art keywords
- allele
- disease
- nucleic acid
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 35
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 18
- 108010002352 Interleukin-1 Proteins 0.000 title claims description 248
- 102000000589 Interleukin-1 Human genes 0.000 title claims description 226
- 238000013518 transcription Methods 0.000 title abstract description 27
- 230000035897 transcription Effects 0.000 title abstract description 25
- 208000035473 Communicable disease Diseases 0.000 title abstract description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 title description 66
- 238000000034 method Methods 0.000 claims abstract description 109
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims abstract description 40
- 102100039065 Interleukin-1 beta Human genes 0.000 claims abstract description 39
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 108700028369 Alleles Proteins 0.000 claims description 246
- 150000007523 nucleic acids Chemical class 0.000 claims description 90
- 102000039446 nucleic acids Human genes 0.000 claims description 85
- 108020004707 nucleic acids Proteins 0.000 claims description 85
- 230000014509 gene expression Effects 0.000 claims description 59
- 230000027455 binding Effects 0.000 claims description 55
- 230000000694 effects Effects 0.000 claims description 55
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 54
- 238000001514 detection method Methods 0.000 claims description 48
- 102000054766 genetic haplotypes Human genes 0.000 claims description 45
- 230000000295 complement effect Effects 0.000 claims description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 206010003246 arthritis Diseases 0.000 claims description 16
- 102000040945 Transcription factor Human genes 0.000 claims description 12
- 108091023040 Transcription factor Proteins 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 201000001245 periodontitis Diseases 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- 208000037803 restenosis Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 230000016396 cytokine production Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 229940126585 therapeutic drug Drugs 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 201000001883 cholelithiasis Diseases 0.000 claims description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- 208000009386 Experimental Arthritis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 198
- 238000011144 upstream manufacturing Methods 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 abstract 2
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract 2
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 description 114
- 108020004414 DNA Proteins 0.000 description 114
- 210000004027 cell Anatomy 0.000 description 110
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 105
- 102000004169 proteins and genes Human genes 0.000 description 104
- 201000010099 disease Diseases 0.000 description 94
- 150000001875 compounds Chemical class 0.000 description 61
- 230000035772 mutation Effects 0.000 description 53
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 51
- 239000000523 sample Substances 0.000 description 51
- 108700019146 Transgenes Proteins 0.000 description 50
- 239000003550 marker Substances 0.000 description 47
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 45
- 108091034117 Oligonucleotide Proteins 0.000 description 43
- 238000012360 testing method Methods 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 42
- 238000003752 polymerase chain reaction Methods 0.000 description 39
- 239000013615 primer Substances 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 230000002103 transcriptional effect Effects 0.000 description 36
- 238000003556 assay Methods 0.000 description 35
- 239000012634 fragment Substances 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 32
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 31
- 230000003321 amplification Effects 0.000 description 31
- 238000003199 nucleic acid amplification method Methods 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 230000009261 transgenic effect Effects 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 29
- 230000004044 response Effects 0.000 description 28
- 229920001184 polypeptide Polymers 0.000 description 25
- 230000003993 interaction Effects 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 238000009396 hybridization Methods 0.000 description 19
- 239000005557 antagonist Substances 0.000 description 18
- 230000002068 genetic effect Effects 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 238000010494 dissociation reaction Methods 0.000 description 17
- 230000005593 dissociations Effects 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 16
- 230000003239 periodontal effect Effects 0.000 description 16
- 229920002477 rna polymer Polymers 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 239000000556 agonist Substances 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 206010065687 Bone loss Diseases 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 230000006798 recombination Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 210000000349 chromosome Anatomy 0.000 description 12
- 239000013068 control sample Substances 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 108091008053 gene clusters Proteins 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000005215 recombination Methods 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 108010051219 Cre recombinase Proteins 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- -1 DNA or RNA Chemical class 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 210000003917 human chromosome Anatomy 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 206010018498 Goitre Diseases 0.000 description 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 6
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108010091086 Recombinases Proteins 0.000 description 6
- 102000018120 Recombinases Human genes 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 210000002064 heart cell Anatomy 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000037230 mobility Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000008718 systemic inflammatory response Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 206010048998 Acute phase reaction Diseases 0.000 description 5
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 5
- 108060002716 Exonuclease Proteins 0.000 description 5
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 208000008312 Tooth Loss Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000004658 acute-phase response Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 4
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 description 4
- 208000001204 Hashimoto Disease Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000034972 Sudden Infant Death Diseases 0.000 description 4
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 206010069363 Traumatic lung injury Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 206010008129 cerebral palsy Diseases 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 201000003872 goiter Diseases 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000007834 ligase chain reaction Methods 0.000 description 4
- 208000018773 low birth weight Diseases 0.000 description 4
- 231100000533 low birth weight Toxicity 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010038997 Retroviral infections Diseases 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000018276 interleukin-1 production Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000001915 proofreading effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 206010062746 Carditis Diseases 0.000 description 2
- 206010063094 Cerebral malaria Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108010046276 FLP recombinase Proteins 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 101150012417 IL1B gene Proteins 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- 102100033502 Interleukin-37 Human genes 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010064550 Myocarditis post infection Diseases 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 208000002392 Rheumatic Nodule Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000002240 Tennis Elbow Diseases 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 206010051222 Toxic oil syndrome Diseases 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000006720 chronic neuroinflammation Effects 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 230000037326 chronic stress Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000022602 disease susceptibility Diseases 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 230000004914 glial activation Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000004047 hyperresponsiveness Effects 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000000495 immunoinflammatory effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000021646 inflammation of heart layer Diseases 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000019189 interleukin-1 beta production Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000009907 neuroendocrine response Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 208000007892 occupational asthma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 230000000010 osteolytic effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003234 polygenic effect Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 201000007529 rheumatic myocarditis Diseases 0.000 description 2
- 101150076141 rn gene Proteins 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- LELMRLNNAOPAPI-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;aminophosphonous acid Chemical compound NP(O)O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LELMRLNNAOPAPI-UFLZEWODSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 101100016363 Caenorhabditis elegans his-67 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101100340738 Homo sapiens IL1B gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000225041 Roestes Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000464 effect on transcription Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003268 heterogeneous phase assay Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000055222 human IL1B Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004939 midgestation embryo Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/204—Modifications characterised by specific length of the oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33168101P | 2001-11-19 | 2001-11-19 | |
| US60/331,681 | 2001-11-19 | ||
| US38602002P | 2002-06-05 | 2002-06-05 | |
| US60/386,020 | 2002-06-05 | ||
| PCT/US2002/037222 WO2003044176A2 (en) | 2001-11-19 | 2002-11-19 | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2467717A1 true CA2467717A1 (en) | 2003-05-30 |
Family
ID=26987865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002467717A Abandoned CA2467717A1 (en) | 2001-11-19 | 2002-11-19 | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20030235890A1 (enExample) |
| EP (1) | EP1463745A4 (enExample) |
| JP (2) | JP4492849B2 (enExample) |
| KR (2) | KR101019131B1 (enExample) |
| CN (2) | CN101955943A (enExample) |
| AU (1) | AU2002359431A1 (enExample) |
| CA (1) | CA2467717A1 (enExample) |
| WO (1) | WO2003044176A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| BR0314552A (pt) * | 2002-09-30 | 2005-08-09 | Novartis Ag | Métodos para prognosticar elevações de colesterol durante terapia imunossupressora |
| US20050175721A1 (en) * | 2004-02-06 | 2005-08-11 | Brovelli Ernesto A. | Method of augmenting the immune-modulatory activity of standardized Echinacea preparations |
| WO2005082070A2 (en) * | 2004-02-26 | 2005-09-09 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
| ES2356167T3 (es) * | 2004-05-03 | 2011-04-05 | Interleukin Genetics, Inc. | Método de diagnóstico y terapia para enfermedades asociadas con un haplotipo inflamatorio il-1. |
| EP1795886A4 (en) * | 2004-08-24 | 2010-04-07 | Fujifilm Corp | METHOD FOR CALCULATING THE DISSOCIATION CONSTANT IN SURFACE PLASMON RESONANCE ANALYSIS |
| JP2006262826A (ja) * | 2005-03-25 | 2006-10-05 | Institute Of Physical & Chemical Research | インターロイキン−１受容体２遺伝子の多型に基づく炎症性疾患の検査法 |
| US8105775B2 (en) | 2005-10-25 | 2012-01-31 | Interleukin Genetics, Inc. | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| JP4870976B2 (ja) * | 2005-11-10 | 2012-02-08 | 株式会社Ｄｎａチップ研究所 | 全血を用いた自己免疫疾患の検査方法 |
| WO2008060627A2 (en) | 2006-11-15 | 2008-05-22 | Interleukin Genetics, Inc. | The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
| US20090170105A1 (en) * | 2007-11-08 | 2009-07-02 | Interleukin Genetics, Inc. | Diagnostics for Aging-Related Dermatologic Disorders |
| CA3011363A1 (en) | 2016-01-12 | 2017-07-20 | Interleukin Genetics, Inc. | Methods for predicting response to treatment |
| KR102543907B1 (ko) * | 2016-06-17 | 2023-06-15 | 서울대학교산학협력단 | 치주질환 위험도 평가용 유전자 마커 |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| JP7097855B2 (ja) * | 2019-04-24 | 2022-07-08 | ジェネシスヘルスケア株式会社 | 歯周病のリスクを判定する方法 |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
| WO2022040090A1 (en) * | 2020-08-17 | 2022-02-24 | The Regents Of The University Of California | Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) * | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
| US4998617A (en) * | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US4968607A (en) * | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5459039A (en) * | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| US5593826A (en) * | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5686246A (en) * | 1995-08-03 | 1997-11-11 | Kornman; Kenneth S. | Detecting genetic predisposition to periodontal disease |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US5698399A (en) * | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
| GB9621129D0 (en) * | 1996-10-10 | 1996-11-27 | Duff Gordon W | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| US6210877B1 (en) | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
| US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
| GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| US6437216B1 (en) * | 1997-11-13 | 2002-08-20 | Interleukin Genetics Inc. | Transgenic models of inflammatory disease |
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| HK1046688A1 (zh) * | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US20030152947A1 (en) * | 2001-06-15 | 2003-08-14 | Crossman David C. | Methods for detecting and treating the early onset of aging-related conditions |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US8071304B2 (en) * | 2003-04-05 | 2011-12-06 | The Johns Hopkins University | Methods for detecting a polymorphism in the NFKB1 gene promoter |
-
2002
- 2002-11-19 EP EP02793968A patent/EP1463745A4/en not_active Withdrawn
- 2002-11-19 KR KR1020047007653A patent/KR101019131B1/ko not_active Expired - Fee Related
- 2002-11-19 WO PCT/US2002/037222 patent/WO2003044176A2/en not_active Ceased
- 2002-11-19 AU AU2002359431A patent/AU2002359431A1/en not_active Abandoned
- 2002-11-19 KR KR1020107016833A patent/KR101059898B1/ko not_active Expired - Fee Related
- 2002-11-19 JP JP2003545801A patent/JP4492849B2/ja not_active Expired - Lifetime
- 2002-11-19 CN CN201010156318.0A patent/CN101955943A/zh active Pending
- 2002-11-19 CN CN02827282.XA patent/CN1753903B/zh not_active Expired - Fee Related
- 2002-11-19 CA CA002467717A patent/CA2467717A1/en not_active Abandoned
- 2002-11-19 US US10/300,011 patent/US20030235890A1/en not_active Abandoned
-
2008
- 2008-03-13 US US12/048,077 patent/US20100279280A1/en not_active Abandoned
-
2009
- 2009-11-16 JP JP2009260743A patent/JP2010029220A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1463745A4 (en) | 2007-11-07 |
| WO2003044176A2 (en) | 2003-05-30 |
| CN101955943A (zh) | 2011-01-26 |
| EP1463745A2 (en) | 2004-10-06 |
| AU2002359431A1 (en) | 2003-06-10 |
| KR20100095652A (ko) | 2010-08-31 |
| WO2003044176A8 (en) | 2003-08-21 |
| KR20040066832A (ko) | 2004-07-27 |
| CN1753903B (zh) | 2010-05-12 |
| CN1753903A (zh) | 2006-03-29 |
| KR101019131B1 (ko) | 2011-03-07 |
| AU2002359431A8 (en) | 2003-06-10 |
| KR101059898B1 (ko) | 2011-08-29 |
| US20100279280A1 (en) | 2010-11-04 |
| WO2003044176A9 (en) | 2003-10-16 |
| JP2010029220A (ja) | 2010-02-12 |
| JP2005509432A (ja) | 2005-04-14 |
| JP4492849B2 (ja) | 2010-06-30 |
| US20030235890A1 (en) | 2003-12-25 |
| WO2003044176A3 (en) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100279280A1 (en) | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases | |
| US20020146700A1 (en) | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype | |
| US20050282198A1 (en) | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype | |
| AU784224B2 (en) | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype | |
| AU785040B2 (en) | Diagnostics and therapeutics for osteoporosis | |
| WO2001016377A9 (en) | Diagnostics and therapeutics for osteoporosis | |
| EP1680513B1 (en) | Diagnostic for osteoporosis | |
| US20080311581A1 (en) | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases | |
| US8105775B2 (en) | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes | |
| US20040171038A1 (en) | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes | |
| EP1751304B1 (en) | Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype | |
| US20080118920A1 (en) | Diagnostics And Therapeutics For Diseases Associated With An Il-1 Inflammatory Haplotype | |
| HK1153504A (en) | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |